BRIEF-Atea Pharmaceuticals Completes Patient Enrollment In Phase 3 C-Forward Trial Evaluating Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus

Atea Pharmaceuticals, Inc.

AVIR

0.00

June 25 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:

ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN PHASE 3 C-FORWARD TRIAL EVALUATING BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS
ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN PHASE 3 C-FORWARD TRIAL EVALUATING BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS
ATEA PHARMACEUTICALS - C-FORWARD TOPLINE RESULTS EXPECTED AROUND YEAR-END 2026
ATEA PHARMACEUTICALS - C-BEYOND PHASE 3 TOPLINE RESULTS EXPECTED MID-YEAR 2026

Source text: ID:nGNXbQGBvw

Further company coverage: AVIR.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.